We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

50 hedge funds and large institutions have $49.3M invested in Catalyst Pharmaceutical in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more capital invested

Capital invested by funds: $25M → $49.3M (+$24.3M)

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

1.76% more ownership

Funds ownership: 28.74% → 30.5% (+1.8%)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

7% less funds holding

Funds holding: 54 → 50 (-4)

Holders
50
Holders Change
-4
Holders Change %
-7.41%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
13
Reduced
10
Closed
10
Calls
$412K
Puts
–
Net Calls
+$412K
Net Calls Change
+$412K

Top Buyers

1
ACA
Avoro Capital Advisors
New York
+$3.39M
2
CS
Candriam SCA
Luxembourg
+$764K
3
BlackRock
BlackRock
New York
+$704K
4
Renaissance Technologies
Renaissance Technologies
New York
+$487K
5
DMK
David M. Knott
+$362K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.78M
2
KCM
Kingdon Capital Management
New York
-$794K
3
TCM
Tanaka Capital Management
New York
-$443K
4
Millennium Management
Millennium Management
New York
-$331K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$63K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$16M – – –
BBA
2
Baker Bros. Advisors
New York
$9.95M – – –
ACA
3
Avoro Capital Advisors
New York
$7.42M +$3.39M +2,663,596 +233%
Vanguard Group
4
Vanguard Group
Pennsylvania
$5.87M +$19.9K +15,600 +0.5%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.71M -$1.78M -1,395,550 -61%
CS
6
Candriam SCA
Luxembourg
$1.17M +$764K +600,000 New
BlackRock
7
BlackRock
New York
$1.08M +$704K +552,803 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$902K +$1.84K +1,446 +0.3%
Renaissance Technologies
9
Renaissance Technologies
New York
$746K +$487K +382,400 New
DMK
10
David M. Knott
$554K +$362K +284,350 New
CA
11
Corrado Advisors
New Jersey
$489K +$77K +60,425 +32%
KCM
12
Kennedy Capital Management
Missouri
$449K -$3.4K -2,671 -1%
TCM
13
Tanaka Capital Management
New York
$416K -$443K -348,130 -59%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$322K -$1.29K -1,013 -0.6%
Deutsche Bank
15
Deutsche Bank
Germany
$266K +$174K +136,788 New
BFM
16
Boothbay Fund Management
New York
$265K +$173K +135,872 New
Northern Trust
17
Northern Trust
Illinois
$217K +$13.9K +10,932 +11%
JP Morgan Chase
18
JP Morgan Chase
New York
$155K +$101K +79,470 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$135K +$3.06K +2,404 +4%
WMSA
20
Weiss Multi-Strategy Advisers
New York
$133K – – –
Millennium Management
21
Millennium Management
New York
$117K -$331K -259,801 -81%
OAM
22
Oxford Asset Management
United Kingdom
$115K +$43.5K +34,181 +138%
ARTA
23
A.R.T. Advisors
New York
$99K -$15.4K -12,093 -19%
State Street
24
State Street
Massachusetts
$88K – – –
AL
25
Agran Libbie
California
$86K – – –
1
2 3

CPRX Hedge Fund Activity: Q1 2017 in Review

50 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2017, worth a combined $49.3M — up 97% from $25M a quarter earlier.

Fund positioning in CPRX was balanced in Q1 2017: 10 funds opened new positions, 10 closed out, 13 added to existing stakes and 10 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $3.39M. The largest seller was Point72 Asset Management, cutting an estimated $1.78M.

  • 50 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2017, down from 54 in Q4 2016.
  • Funds reported $49.3M of Catalyst Pharmaceutical stock for Q1 2017, up 97% quarter-over-quarter.
  • 10 funds opened new Catalyst Pharmaceutical positions in Q1 2017 and 10 closed out, a net change of 0 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2017 was Avoro Capital Advisors, an estimated $3.39M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2017 was Point72 Asset Management, an estimated $1.78M sold.

Based on aggregated 13F filings for Q1 2017.